A computational assay to design an epitope-based peptide vaccine against chikungunya virus

Future Virology

Volumn 7, Issue 10, 2012, Pages 1029-1042

  Islam, Rezaul ^a   Sakib, M Sadman ^a   Zaman, Aubhishek ^a  

^a UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

chikungunya virus; CHIKV; E2 envelope protein; epitope based drug design

Indexed keywords

E2 PROTEIN; EPITOPE; HLA ANTIGEN; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; PROTEOME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALLELE; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; ASSAY; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CHIKUNGUNYA ALPHAVIRUS; DATA BASE; DRUG DESIGN; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HLA SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPRODUCIBILITY; T LYMPHOCYTE; TOGAVIRUS; VALIDATION PROCESS;

EID: 84867654767     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.95     Document Type: Article

References (55)

1. Islam MN, Hossain MA, Khaleque MA et al. Chikungunya virus infection, a threat to public health. Mymensingh Med. J. 21(2), 372-376 (2012).
2. Zayed A, Awash AA, Esmail MA et al. Detection of chikungunya virus in Aedes aegypti during 2011 outbreak in Al Hodayda, Yemen. Acta Trop. 123(1), 62-66 (2012).
3. Rohani A, Potiwat R, Zamree I, Lee HL, Refractoriness of Aedes aegypti (Linnaeus) to dual infection with dengue and chikungunya virus. Southeast Asian J. Trop. Med. Public Health 40(3), 443-448 (2009).
4. Tang BL. The cell biology of chikungunya virus infection. Cell. Microbiol. 4(9), 1354-1363 (2012).
5. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur. J. Intern. Med. 23(4), 325-329 (2012).
6. Joubert PE, Werneke SW, de la Calle C et al. Chikungunya virus-induced autophagy delays caspase-dependent cell death. J. Exp. Med. 209(5), 1029-1047 (2012).
7. Pellot AS, Alessandri JL, Robin S et al. [Severe forms of chikungunya virus infection in a pediatric intensive care unit on Reunion Island]. Med. Trop. (Mars) 72(Spec. No), 88-93 (2012).
8. Ng LF, Ojcius DM. Chikungunya fever - re-emergence of an old disease. Microbes Infect. 11(14-15), 1163-1164 (2009).
9. Her Z, Kam YW, Lin RT, Ng LF. Chikungunya: a bending reality. Microbes Infect. 11(14-15), 1165-1176 (2009).
10. Aoustin T. [Chikungunya and urban sprawl on Reunion Island]. Med. Trop. (Mars) 72(Spec. No), 51-59 (2012).
11. Baville M, Dehecq JS, Reilhes O, Margueron T, Polycarpe D, Filleul L. [New vector control measures implemented between 2005 and 2011 on Reunion Island: lessons learned from chikungunya epidemic]. Med. Trop. (Mars) 72(Spec. No), 43-46 (2012).
12. Larrieu S, Balleydier E, Renault P, Baville M, Filleul L. [Epidemiological surveillance du chikungunya on Reunion Island from 2005 to 2011]. Med. Trop. (Mars) 72(Spec. No), 38-42 (2012).
13. Long KM, Heise MT. Chikungunya virus transmission - more than meets the eye. J. Infect. Dis. 206(6), 806-807 (2012).
14. Stojcic I. [Chikungunya epidemic in 2005-2006: questions from occupational health professionals]. Med. Trop. (Mars) 72(Spec. No), 103-104 (2012).
15. Kurkela S, Sane J, Deren E et al. Chikungunya virus as a causative agent of fever of unknown origin in Finnish travellers to tropics. J. Clin. Virol. 54(3), 289-290 (2012).
16. Gerardin P, Fianu A, Malvy D et al. [Perceived morbidity and community burden of chikungunya in La Reunion]. Med. Trop. (Mars) 72(Spec. No), 76-82 (2012).
17. Flahault A, Aumont G, Boisson V et al. An interdisciplinary approach to controlling chikungunya outbreaks on French islands in the south-west Indian ocean. Med. Trop. (Mars) 72(Spec. No), 66-71 (2012).
18. Moro ML, Grilli E, Corvetta A et al. Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study. J. Infect. 65(2), 165-172 (2012).
19. Idelson B. [Chikungunya crisis on Reunion Island. Media coverage and conficting public information]. Med. Trop. (Mars) 72(Spec. No), 25-28 (2012).
20. Boisson V, Cresta MP, Thibault L et al. [Chikungunya outbreak on Reunion Island in 2005/2006: role of hospital physicians in raising alert]. Med. Trop. (Mars) 72(Spec. No), 19-22 (2012).
21. Jacques C, Bernard-Alex G, Fabrice S. [Lessons learned from the health crisis caused by the chikungunya epidemic on Reunion Island in 2005-2006]. Med. Trop. (Mars) 72(Spec. No), 4-5 (2012).
22. Nagpal BN, Saxena R, Srivastava A et al. Retrospective study of chikungunya outbreak in urban areas of India. Indian J. Med. Res. 135, 351-358 (2012).
23. Vilain P, Larrieu S, Renault P, Baville M, Filleul L. How to explain the re-emergence of chikungunya infection in Reunion Island in 2010? Acta Trop. 123(2), 85-90 (2012).
24. Shrinet J, Jain S, Sharma A et al. Genetic characterization of chikungunya virus from New Delhi reveal emergence of a new molecular signature in Indian isolates. Virol. J. 9(1), 100 (2012).
25. Akahata W, Nabel GJ. A specifc domain of the chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J. Virol. 86(16), 8879-8883 (2012).
26. Kuo SC, Chen YJ, Wang YM et al. Cell-based analysis of chikungunya virus E1 protein in membrane fusion. J. Biomed. Sci. 19, 44 (2012).
27. Singh RK, Tiwari S, Mishra VK, Tiwari R, Dhole TN. Molecular epidemiology of chikungunya virus: mutation in E1 gene region. J. Virol. Methods 185(2), 213-220 (2012).
28. Boere WA, Harmsen T, Vinjé J, Benaissa-Trouw BJ, Kraaijeveld CA, Snippe H. Identifcation of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities. J. Virol. 52(2), 575-582 (1984). (Pubitemid 15206330)
29. Frazier CL, Shope RE. Detection of antibodies to alphaviruses by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 10(4), 583-585 (1979). (Pubitemid 10250196)
30. Hunt AR, Roehrig JT. Biochemical and biological characteristics of epitopes on the E1 glycoprotein of western equine encephalitis virus. Virology 142(2), 334-346 (1985). (Pubitemid 17200510)
31. Ahn A, Klimjack MR, Chatterjee PK, Kielian M. An epitope of the Semliki Forest virus fusion protein exposed during virusmembrane fusion. J. Virol. 73(12), 10029-10039 (1999).
32. Shukla J, Khan M, Tiwari M et al. Development and evaluation of antigen capture ELISA for early clinical diagnosis of chikungunya. Diagn. Microbiol. Infect. Dis. 65(2), 142-149 (2009).
33. Byrnes AP, Griffn DE. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72(9), 7349-7356 (1998). (Pubitemid 28377866)
34. Fraser JR, Cunningham AL. Incubation time of epidemic polyarthritis. Med. J. Aust. 1(11), 550-551 (1980).
35. Lee CY, Kam Y W, Fric J et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 7(12), e1002390 (2011).
36. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J. Infect. Dis. 204(1), 115-123 (2011).
37. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P et al. Persistent chronic infammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J. Immunol. 184(10), 5914-5927 (2010).
38. Klavinskis LS, Whitton JL, Oldstone MB. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63(10), 4311-4316 (1989). (Pubitemid 19229428)
39. Tan P T, Khan AM, August JT. Highly conserved infuenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum. Vaccin. 7(4), 402-409 (2011).
40. Olsen LR, Zhang GL, Keskin DB, Reinherz EL, Brusic V. Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using peptide block entropy. Front. Immunol. 2, 69 (2011).
41. Schuffenecker I, Iteman I, Michault A et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3(7), e263 (2006).
42. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. Genome Res. 14(6), 1188-1190 (2004). (Pubitemid 38811555)
43. Larsen MV, Lundegaard C, Lamberth K et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport effciency, and proteasomal cleavage predictions. Eur. J. Immunol. 35(8), 2295-2303 (2005). (Pubitemid 41179750)
44. Jojic N, Reyes-Gomez M, Heckerman D, Kadie C, Schueler-Furman O. Learning MHC I-peptide binding. Bioinformatics 22(14), e227-e235 (2006).
45. Singh H, Raghava G. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19(8), 1009-1014 (2003). (Pubitemid 36675822)
46. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3), 213-219 (1999). (Pubitemid 30099526)
47. Maupetit J, Derreumaux P, Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic acids Res. 37(Suppl. 2), W498-W503 (2009).
48. Kolaskar A, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276(1), 172-174 (1990).
49. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112(8), 3303-3311 (2008).
50. Senanayake MP, Senanayake SM, Vidanage KK, Gunasena S, Lamabadusuriya SP. Vertical transmission in chikungunya infection. Ceylon Med. J. 54(2), 47-50 (2009).
51. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin. Infect. Dis. 49(6), 942-948 (2009).
52. Sbai H, Mehta A, DeGroot AS. Use of T cell epitopes for vaccine development. Curr. Drug Targets Infect. Disord. 1(3), 303-313 (2001).
53. Medical Microbiology (Fourth edition). Baron S (Ed.). University of Texas, Medical Branch in Galveston, TX, USA (1996).
54. Griffn DE. Roles and reactivities of antibodies to alphaviruses. Semin. Virol. 6(4), 249-255 (1995).
55. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. Hepatol. 54(6), 1273-1285 (2011).